Description:
Reference Number:1683
Background
MRSA (methicillin resistant S. aureus) is a potential killer infection that
is endemic in our hospitals. Around 20% of the general population (patients,
staff, hospital visitors) are believed to be carriers with potential to cause
infection. Recent focus on cleanliness in hospitals and introduction of
antiseptic handgels in wards has been partially successful in reducing
infection. However, S.aureus is carried by the general population in their nasal
passages (including patients, staff and visitors to our hospitals) which is not
addressed by handwashes. Further, existing nasal treatments have inherent
problems of rapid clearance due to mucocillary action and have failed to stop
the spread of MRSA.
Technology
A research team at the University of Strathclyde has demonstrated that the
use of novel formulations results in rapid adherence to the nasal mucosa by
formation of viscous gels that resist removal by cilia. A sustained absorption
profile is obtained, leading to reduced frequency of dosing. The novel nasal
formulations (NNF) are virtually sensation free and afford prolonged residence
in man.
Key Benefits
- Reduction in MRSA infections in hospitals
- Decreased lengths of hospital stay
- Prevention of healthcare associated infections
- Technology can be applied to a wide spectrum of drug
- Cleaner and more convenient to use than creams or ointments
- Prolonged duration of action avoids the repeat dosing required by current
products
Markets and Applications
The novel nasal formulations could be used to treat the entire patient, staff
and (perhaps) visitor population frequenting our hospitals. This could mean the
treatment of in excess of 150,000 staff and a significant number of the 1.6
milllion elective stay patients in the UK. This technology could also be applied
to many other drugs and therapeutic situations.
Licensing and Development
The technology is a novel finding that constitutes a patentable invention.
The IP is protected through non-disclosure and contact is welcomed from
organisations interested in developing or exploiting this technology.
For further information, please contact Research & Kowledge Exchange
Services:
e: rkes@strath.ac.uk t: 0141 548 3707 f: 0141 552
4409